Wellgistics Health Files S-1/A Amendment

Ticker: WGRX · Form: S-1/A · Filed: Dec 6, 2024 · CIK: 2030763

Sentiment: neutral

Topics: ipo, registration-statement, amendment

TL;DR

Wellgistics Health (fka Danam Health) filed S-1/A. IPO incoming?

AI Summary

Wellgistics Health, Inc. (formerly Danam Health, Inc.) filed an S-1/A amendment on December 6, 2024, for its registration statement. The company, incorporated in Delaware, is in the wholesale drug proprietaries and druggists' sundries sector. Its principal executive offices are located at 3000 Bayport Drive, Suite 950, Tampa, FL 33607.

Why It Matters

This filing indicates Wellgistics Health is moving forward with its public offering process, which could lead to increased liquidity and capital for the company's operations.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it represents a company in the process of going public, which inherently carries risks associated with market reception and operational scaling.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1/A filing?

This is an amendment (Amendment No. 5) to the Form S-1 Registration Statement filed by Wellgistics Health, Inc. to update information related to its public offering.

When was this amendment filed?

The filing was made on December 6, 2024.

What was Wellgistics Health, Inc. formerly known as?

The company was formerly known as Danam Health, Inc., with a name change date of July 17, 2024.

Where are Wellgistics Health's principal executive offices located?

The principal executive offices are located at 3000 Bayport Drive, Suite 950, Tampa, FL 33607.

Who is listed as the agent for service for Wellgistics Health, Inc.?

Timothy Canning is listed as the agent for service, located at 3000 Bayport Drive, Suite 950, Tampa, FL 33607.

Filing Stats: 4,128 words · 17 min read · ~14 pages · Grade level 14.4 · Accepted 2024-12-06 16:45:53

Key Financial Figures

Filing Documents

Underwriting

Underwriting discount (1) $ 0.35 $ 315,000 Proceeds, before expenses, to us (2) $ 4.65 $ 4,185,000 (1) We have agreed to pay the representative a discount equal to 7% of the gross proceeds of the Offering. For a description of the other compensation to be received by the representative, see “ Underwriting ” beginning on page 101. (2) Excludes fees and expenses payable to the underwriters and other expenses of this Offering. The underwriters are offering the units on a firm commitment basis and expects to deliver the Common Stock to purchasers on or about [], 2024. Craft Capital Management LLC D. Boral Capital LLC The date of this prospectus is [], 2024 TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS 1 MARKET AND INDUSTRY DATA 1 FREQUENTLY USED TERMS 2 PROSPECTUS SUMMARY 5 THE OFFERING 9 RISK FACTORS 10 CAUTIONARY 41 USE OF PROCEEDS 42 DIVIDEND POLICY 43 CAPITALIZATION 44

DILUTION

DILUTION 45 SELECTED FINANCIAL DATA 46 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION 47 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF WELLGISTICS HEALTH, INC. 51 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF WELLGISTICS LLC 56

BUSINESS

BUSINESS 63 MANAGEMENT 81 EXECUTIVE COMPENSATION 86 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 90 PRINCIPAL STOCKHOLDERS 92 DESCRIPTION OF CAPITAL STOCK 93 SHARES ELIGIBLE FOR FUTURE SALE 96 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES 97

UNDERWRITING

UNDERWRITING 101 LEGAL MATTERS 105 EXPERTS 105 WHERE YOU CAN FIND MORE INFORMATION 105 INDEX TO FINANCIAL STATEMENTS F-1 DEALER PROSPECTIVE DELIVERY OBLIGATION Until [ ] (the 25th day after the date of this offering), all dealers that effect transactions in these securities, whether or not participating in this Offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. i ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus or in any related free-writing prospectus. We and the underwriters have not authorized anyone to provide you with information or to make any representations other than contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information appearing in this prospectus, any post-effective amendment, and any applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not making an offer to sell our Common Stock in any jurisdiction where the offer or sale thereof is not permitted. You should not assume that the information appearing in this prospectus any post-effective amendment, and any applicable prospectus supplement to this prospectus is accurate as of any date other than their respective dates. Our business, financial condition, results of operations and prospects may have changed since those da

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing